المؤلفون: Segura J; Department of Nephrology, Hospital 12 de Octubre, Madrid, Spain., Ruilope LM

المصدر: Vascular health and risk management [Vasc Health Risk Manag] 2013; Vol. 9, pp. 521-8. Date of Electronic Publication: 2013 Sep 16.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Review

بيانات الدورية: Publisher: Dove Medical Press Country of Publication: New Zealand NLM ID: 101273479 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1178-2048 (Electronic) Linking ISSN: 11766344 NLM ISO Abbreviation: Vasc Health Risk Manag Subsets: MEDLINE

مواضيع طبية MeSH: Amlodipine/*therapeutic use , Angiotensin II Type 1 Receptor Blockers/*therapeutic use , Antihypertensive Agents/*therapeutic use , Benzimidazoles/*therapeutic use , Benzoates/*therapeutic use , Blood Pressure/*drug effects , Calcium Channel Blockers/*therapeutic use , Diuretics/*therapeutic use , Hydrochlorothiazide/*therapeutic use , Hypertension/*drug therapy, Administration, Oral ; Amlodipine/administration & dosage ; Amlodipine/adverse effects ; Angiotensin II Type 1 Receptor Blockers/administration & dosage ; Angiotensin II Type 1 Receptor Blockers/adverse effects ; Antihypertensive Agents/administration & dosage ; Antihypertensive Agents/adverse effects ; Benzimidazoles/administration & dosage ; Benzimidazoles/adverse effects ; Benzoates/administration & dosage ; Benzoates/adverse effects ; Calcium Channel Blockers/administration & dosage ; Calcium Channel Blockers/adverse effects ; Diuretics/administration & dosage ; Diuretics/adverse effects ; Drug Combinations ; Humans ; Hydrochlorothiazide/administration & dosage ; Hydrochlorothiazide/adverse effects ; Hypertension/diagnosis ; Hypertension/physiopathology ; Tablets ; Telmisartan ; Time Factors ; Treatment Outcome